Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment

Launched by CHINESE UNIVERSITY OF HONG KONG · Feb 28, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how patients with metastatic prostate cancer and their doctors weigh the risks and benefits of different treatment options. The goal is to understand what factors are most important to both patients and physicians when deciding on treatment, particularly for those at various stages of the disease. The study is currently recruiting male participants aged 18 and older who have been diagnosed with metastatic prostate cancer within the last five years.

To participate, individuals need to be able to read and write, and they must be willing to provide informed consent. Unfortunately, those who cannot complete a survey on their own due to physical or psychological issues will not be eligible. If you choose to participate, you can expect to share your thoughts and preferences regarding treatment options, helping to shape future care for prostate cancer patients. Your input is valuable and can make a difference in understanding how to balance treatment risks and benefits better.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • aged 18 years or older,
• • diagnosis of metastatic prostate cancer within 5 years,
• • able to read and write,
• • accepting and signing the informed consent
• Exclusion Criteria:
• • if patients are unable to complete the survey by themselves due to physical or psychological reasons,
• • deemed ineligible by treating physicians if patients are unable to complete the survey by themselves due to physical or psychological reasons,
• • deemed ineligible by treating physicians